Why AstraZeneca Covid-19 vaccine approval ‘good news for whole world’? UK minister answers
After British regulators on Wednesday approved AstraZeneca’s vaccine to provide immunity against the coronavirus disease (Covid-19), UK health minister Matt Hancock said the approval was “good news for the whole world”. Speaking to Sky News, Hancock highlighted the advantages of AstraZeneca’s vaccine, developed at Oxford University, over other Covid-19 vaccines in terms of cost and storage feasibility.
“It’s good news for the whole world because this vaccine is relatively cheap to produce...because it’s relatively easy to handle and just can be stored at a normal fridge temperature,” he said.
Hancock denied setting a target for vaccinating everyone, however, the UK minister added that he hopes the country “will be able to get out of this by the spring.” He also admitted that the National Health Service (NHS) has been facing a huge amount of pressure due to the surge in Covid-19 cases, saying the vaccine “doesn’t take away from the really difficult winter weeks that we’ve got between now and then”.
Also Read | New spike in UK cases as Oxford-AstraZeneca vaccine is approved
The Oxford/AstraZeneca Covid-19 vaccine, AZD1222, can be stored at fridge temperature of 2°C to 8°C for at least six months, while Pfizer/BioNTech and Moderna vaccines need to be stored at a much colder temperature. Pfizer’s vaccine needs ultra-cold storage at around -75°C and can be kept in the fridge for five days. On the other hand, Moderna’s vaccine, mRNA-1273, has to be stored at -20°C and is expected to remain stable at standard refrigerated conditions for up to 30 days.
The Oxford/AstraZeneca vaccine also scores better on pricing as it costs a fraction of the price set by Pfizer and Moderna and will be manufactured in multiple low- and middle-income countries, including India and Brazil. Last month, Adar Poonawalla, chief executive officer of Serum Institute of India (SII), had told Hindustan Times that the vaccine will be priced in India at Rs 500-600. SII has partnered with AstraZeneca to conduct clinical trials and manufacture the vaccine in India.
The Phase 3 trials of AZD1222 against SARS-CoV-2 across two different dose regimens showed an average efficacy of 70.4%, with no hospitalisations or severe disease observed in the vaccinated groups from three weeks after the first dose. The efficacy results are based on data obtained from 11,636 volunteers across the United Kingdom and Brazil.
Less time to read?
Try Quickreads
-
Covid-19: A third of US should be considering masks, officials say
Covid-19 cases are increasing in the United States — and could get even worse over the coming months, federal health officials warned Wednesday in urging areas hardest hit to consider reissuing calls for indoor masking. Increasing numbers of Covid-19 infections and hospitalizations are putting more of the country under guidelines issued by the US Centers for Disease Control and Prevention that call for masking and other infection precautions.
-
New York: 911 dispatcher who took Buffalo shooting call put on leave
A 911 dispatcher has been placed on leave and may lose her job after allegedly hanging up on an supermarket employee hiding during this weekend's shooting rampage in Buffalo, New York. “Termination will be sought” for the dispatcher at a disciplinary hearing later this month, said spokesperson for the executive of Erie County, Peter Anderson, in an email to The Associated Press on Wednesday. Anderson said it's unclear who hung up on whom.
-
Sri Lanka economic crisis: CID interrogates 4 MPs over attacks on protesters
A team of Sri Lanka's Criminal Investigations Department have questioned four Members of Parliament (MPs), including two former ministers, over last week's violence against protesters at two protest sites in Colombo, the country's largest city, local media has reported. According to reports, a CID team arrived at the Parliament Complex on Wednesday to interrogate--with the Speaker's permission--and record the statements of Rohitha Abeygunawardena and CB Ratnayake, both former ministers.
-
US reports 1st monkeypox case of 2022: 10 things to know
Though this is the first confirmed case in the United States, the US Centers for Disease Control and Prevention is preparing for the possibility of more monkeypox cases. Here are 10 things to know about monkeypox and the 1st case in the United States in 2022 1. The Massachusetts man travelled to Canada at the end of April to meet friends and returned in early May. This is the first case of monkeypox this year.
-
N.Korea ramping up production of drugs, medical supplies to fight Covid: Report
North Korea is ramping up the production of drugs and medical supplies to combat the Covid-19 pandemic, which has wreaked havoc. According to the Korean Central News Agency on Thursday, North Korea is also increasing the production of traditional Korean medicines used to reduce fever and pain. In the capital city of Pyongyang and nearby regions, factories are churning out more injections, medicines and thermometers and other medical supplies.
